Emerging Markets and Market Upsides
LINC's plan focuses largely on the US market, although there are
significant opportunities for anti-fibrotic technology outside of the US.
The European market alone for lung care therapeutics is approximately
40% of the US market, representing an additional several billion dollars
in market potential.
The Asian and European markets for lung care products present
significant upsides for the LINC technology. For example, the incidence
of emphysema in Japan is as high as 3% of the population over age 50,
and most of these cases are associated with smoking. The incidence of
fibrotic lung diseases is also growing in Europe, fueled in part by the
large number of adults who have smoked for many years. In addition to
these lung disorders, the LINC technology has applications in other
disorders which have a fibrotic component. These include dermal
conditions (keloids or other scarring of the skin), post-surgical adhesions,
and possibly diseases such as cirrhosis of the liver.
|
